LGALS4

Across TCGA pan-cancer cohorts, LGALS4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LGALS4 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LGALS4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LGALS4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, HNSC, and COAD are the cancer types where LGALS4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.684	0.386	<.001	100	view →
HNSC	DFS	Tertile	All	0.842	0.984	.022	7	view →
COAD	DFS	Median	III,IV	1.000	0.898	.046	6	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	3	view →
CCRCC	DFS	Quartile	All	0.887	1.000	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LGALS4–PDAC (OS)

Open the PDAC breakdown →